Amgen/J&J Procrit arbitration
Executive Summary
Johnson & Johnson will retain license to sell Procrit (epoetin alfa) in the U.S. following Oct. 18 decision by an arbitration panel, but will pay Amgen $150 mil. in damages. J&J is seeking attorneys' fees. Amgen argued that J&J intentionally sold Procrit in Amgen's exclusive dialysis market, violating a 1985 agreement between the companies. Amgen sells epoetin alfa as Epogen for dialysis patients, while J&J sells Procrit in non-dialysis markets (1"The Pink Sheet" March 20, 2000, p. 19)...